This study was designed to investigate the prostate cancer-specific tumoricidal effect of the suicide gene, Escherichia coli uracil phosphoribosyltransferase (UPRT), driven by the human prostatespecific membrane antigen promoter/enhancer (PSMA E/P ) in vitro. When transfected with PSMA E/ P -EGFP (enhanced green fluorescence protein) (a plasmid construct with the green fluorescence protein gene driven by the PSMA E/P ), only the androgen-responsive and PSMA-positive prostate cancer cell line, LNCaP, expressed GFP, indicating the specificity of the PSMA E/P activity in androgen-sensitive and PSMA-positive prostate cancer cells. Taking advantage of this prostate cancer-specific property of PSMA E/P , we successfully introduced bacterial UPRT into LNCaP cells where the tumoricidal effect of 5-fluorouracil (5-FU) was significantly increased when compared with the cells without the exogenous UPRT. We conclude that the efficacy of 5-FU-based chemotherapy in prostate cancers can be significantly improved by targeted expression of the suicide gene UPRT under the control of PSMA E/P .
Introduction
Prostate cancer is the second most commonly diagnosed cancer in the human male population worldwide. Androgen ablation has become a commonly used initial strategy to treat prostate cancer patients with a fairly good clinical outcome, 1 since its discovery in early 1940s. 2 However, most patients eventually develop resistance to further manipulation of this hormone. As a result, more aggressive treatment strategies have to be considered for patients with androgen-independent or hormonerefractory prostate cancer, 3, 4 among which 5-fluorouracil (5-FU)-based chemotherapy looks promising. 5 5-Fluorouracil is a pharmacologically nontoxic compound or prodrug, which has been widely used in chemotherapy for a wide range of metastatic tumors including hormone-refractory prostate cancer. 6, 7 Upon facilitated diffusion into the cell, 5-FU is enzymatically converted into three major metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorouridine triphosphate (FUTP) and fluorodeoxyuridine triphosphate (FdUTP). 7 FdUMP blocks DNA synthesis by inhibiting the activity of thymidylate synthase, and FUTP and FdUTP interfere with normal nucleotide synthesis by direct incorporation into RNA and DNA molecules, thereby achieving the drug cytotoxicity of 5-FU. 7 Although 5-FU can be converted into the above cytotoxic metabolites, FdUMP, FUTP and FdUTP, a substantial proportion of administrated 5-FU is rapidly degraded intracellularly by dihydropyrimidine dehydrogenase (DPD), generating non-cytotoxic product dihydropyrimidine and thus significantly reducing the chemosensitivity of tumor cells to 5-FU. 8, 9 One of the recently developed strategies to circumvent this DPD-associated pathway of 5-FU metabolism is to deliver into the tumor cell a gene of Escherichia. coli origin that encodes uracil phosphoribosyl transferase (UPRT), based on the idea of suicide gene therapy that was first described by Moolten in 1986. 10 As a suicide gene, UPRT is generally believed not present in humans (the cloning of human UPRT has been recently reported but no detectable activity of this human enzyme has been demonstrated 11 ). Once introduced into and expressed in the tumor cell, the bacterial UPRT rapidly and directly converts 5-FU into FUMP, thus bypassing the DPDcatalyzed 5-FU degradation into inactive metabolites. It is encouraging that numerous in vitro and in vivo studies have demonstrated that the UPRT-based suicide gene therapy alone or in combination with other approaches is able to significantly increase the efficacy of 5-FU as a chemotherapeutic agent in various types of cancers, [12] [13] [14] including prostate cancer. 15 However, it is highly desirable and clinically more important that the expression of suicide gene(s) can be more specifically confined to tumor but not normal cells. Taking advantage of the specific activity of the promoter and enhancer of the human prostate-specific membrane antigen (PSMA) in prostate cancer cells, Ikegami et al. 16 have developed a functional, prostate cancer-specific herpes virus thymidine kinase-based suicide gene therapy. Similarly, we have successfully constructed an expression vector (PSMA E/P -UPRT) in which the UPRT gene of E. Coli is placed under the control of the human PSMA E/P . 17 In this study, we sought to investigate whether this PSMA E/P was able to drive expression of this suicide gene and thus increase the tumoricidal effect of 5-FU specifically in PSMA-positive prostate cancer cells in vitro.
Materials and methods

Cell culture
Prostate cancer cell lines, LNCaP and PC-3, and nonprostate cancer cell line, MCF-7, were obtained from the Transplantation and Immunology Laboratory, West China Hospital affiliated with Sichuan University, China. For maintenance, they were cultured in RPMI-1640 (Gibco, Rockville, MD, USA) supplemented with 10% fetal bovine serum (Gibco, Melbourne, Australia) and antibiotics (100 mg ml À1 streptomycin and 100 IU ml À1 penicillin, North China Pharmaceutical CO., Ltd, China) at 37 1C under 5% CO 2 and humidified atmosphere.
Evaluation of cell type-specific activity of the PSMA E/P LNCaP, PC-3 and MCF-7 cells were plated in a 24-well plate at 5 Â 10 4 cells per well. Upon growth to 70-80% confluence in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics, the cells were transfected with PSMA E/P -EGFP (enhanced green fluorescence protein), a plasmid construct with EGFP driven by the human PSMA E/P , 17 using LIPOFECTAMINE 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After 24-48 h culture in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics, the transfectants were checked under a fluorescence microscope for the expression of EGFP as direct evidence of the activity of the human PSMA E/P . Both fluorescent and visible light images were captured of the cells in the same microscopic field for each cell type.
Establishment of stable LNCaP clones expressing UPRT or EGFP
LNCaP cells were plated in a 6-well plate at 5 Â 10 5 cells per well and transfected, by following the same procedure as described above, with PSMA E/P -UPRT, a plasmid construct with the E. coli UPRT-coding sequence under the control of the human PSMA E/P and a neomycin-resistance gene driven by the early promoter of the SV40T antigen. 17 Forty-eight hours after transfection, the cells were subcultured onto a 24-well plate and subject to selection of clones stably expressing the bacterial UPRT based on the ability of the PSMA E/P -UPRT-positive but not negative cells to resist to G418 (geneticin) due to the function of the neomycin-resistance gene product. The selection was performed in the presence of 750 mg ml À1 G418 (Gibco) for 2 weeks during which the culture medium was changed every 2-3 days with fresh G418 added at each medium change. This concentration of G418 was chosen on the basis of a preceding experiment where 750 mg ml À1 was demonstrated to be the minimum dose causing detachment, fragmentation and eventual death of untransfected LNCaP cells when various doses (200-1000 mg ml
À1
) of G418 were tested (data not shown). At the end of the G418 selection, positive clones were picked up and propagated in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics. For the purpose of control in the tumoricidal analyses as discussed below, stable clones were similarly selected and propagated from the LNCaP cells transfected with PSMA E/P -EGFP as described in the preceding section. To confirm the authentic PSMA-E/P -driven expression of UPRT in the selected clones from the cells transfected with PSMA E/P -UPRT, total RNA was extracted using TRIzol reagent (Invitrogen) and subject to a reverse transcription (RT)-PCR analysis of the bacterial UPRT mRNA using a pair of primers (5 0 -CGGGATCCATGAAGATCGTGGAAGTCAA ACACC-3 0 and 5 0 -GGGGGAATGCGGCCGCTTATTTCG TACCAAAGATTTTGTCA-3 0 ) and human b-actin using a pair of primers (5 0 -GCGGGAAATCGTGCGTGACATT-3 0 and 5 0 -GATGGAGTTGAAGGTAGTTTCGTG-3 0 ) designed using the software Primer Premier 5.0 (Premier Inc., Canada) and synthesized by Genebase (Shanghai, China). As a negative control, the selected clones from the PSMA E/P -EGFP transfectants were also subject to the RT-PCR analysis.
Evaluation of tumoricidal activity of the UPRT/5-FU suicide gene system in prostate cancer cells
To this end, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and flow cytometric analysis were performed. For MTT assay, untransfected LNCaP cells and the LNCaP cells that stably expressed UPRT or GFP were plated in 96-well plates at 5 Â 10 3 cells per well. After culture at 37 1C under 5% CO 2 and humidified atmosphere for 24 h, the cells were incubated in triplicate with 0, 0.1, 1, 10, 100 and 1000 mM 5-FU (Sigma, St Louis, MS, USA) for 48 h, followed by addition of 20 ml MTT (Sigma) to each well. At the end of the incubation with MTT for 4 h, 150 ml dimethyl sulfoxide was added to each well and the optical density at 570 nm (OD 570 ) was measured on a microplate reader. Percent inhibition of cell growth was calculated for each of the UPRT/5-FU-targeted control of PSMAE/P treats prostate cancer FJ Zhao et al cell type and 5-FU concentration combinations. For flow cytometric analysis, untransfected LNCaP cells and the LNCaP cells that stably expressed UPRT or GFP were plated in 6-well plates at 5 Â 10 4 cells per well. After culture at 37 1C under 5% CO 2 and humidified atmosphere for 24-48 h, the cells were incubated with 15 mM 5-FU for 48 h. Both floating and attached cells were collected and washed once with 1 Â phosphate-buffered saline. The cell pellet was resuspended in cold phosphate-buffered saline and fixed in 70% ethanol at 4 1C overnight. After centrifugation, the cells were stained with propidium in the assay buffer at 4 1C for 20-30 min before gated at 488 nm on FACSCalibur Flow Cytometry machine (Becton Dickinson, San Jose, CA, USA).
Statistical analysis
All data were presented as the mean±s.d. and analyzed by analysis of variance in combination with t-test for multiple comparison.
Results
PSMA-positive LNCaP-specific activity of the PSMA E/P
To determine whether the activity of the PSMA E/P was cell type-specific, we evaluated the expression of EGFP driven by the human PSMA E/P in androgen-dependent (LNCaP) or -independent (PC-3) prostate cancer cells as well as non-prostate cancer (MCF-7) cells. When transiently transfected with the plasmid vector containing the GFP-coding sequence under the control of the PSMA E/P , 17 only the androgen-dependent and PSMApositive prostate cancer cell LNCaP expressed GFP (Figure 1) .
PSMA E/P -driven expression of bacterial UPRT in LNCaP cells
Given that the PSMA E/P was active only in the PSMApositive prostate cancer cell line LNCaP, we next examined whether this PSMA E/P was able to drive expression of the bacterial UPRT specifically in this cell line. To do that, we transfected LNCaP cells with a previously constructed plasmid vector containing the bacterial UPRT gene under the control of the human PSMA E/P and a neomycin-resistance gene driven by the promoter of the SV-40T antigen 17 and performed stable clone selection using G418. For the purpose of control in further analysis of the tumoricidal effect of the suicide gene system, UPRT/5-FU, stable selection was also carried out in LNCaP cells transfected with PSMA E/P -GFP. In contrast to the easy confirmation of the positive clones expressing GFP by direct fluorescence microscopy, analysis of the bacterial UPRT mRNA by RT-PCR was performed to confirm whether the clones selected from cells transfected with PSMA E/P -UPRT were truly UPRTpositive. As shown in Figure 2 , b-actin mRNA was present in both clones selected from the LNCaP cells transfected, respectively, with PSMA E/P -UPRT and PSMA E/P -GFP (Figure 2a ), but the bacterial UPRT mRNA was detected only in the clone selected from the cells transfected with PSMA E/P -UPRT (Figure 2b) .
Enhancement of the tumoricidal activity of 5-FU by UPRT
To investigate whether the human PSMA E/P -driven expression of the bacterial UPRT in the PSMA-positive prostate cancer LNCaP cells was able to enhance the efficacy of 5-FU as a chemotherapeutic agent by facilitating its conversion to a more cytotoxic metabolite, we analyzed the 5-FU-induced cell growth inhibition in untransfected LNCaP cells and stable clones of LNCaP cells expressing EGFP or UPRT. As determined in MTT assays, the percent inhibition of cell growth, calculated against the control (that is, 0 mM), increased with the dose Figure 1 Direct microscopic evaluation of cell type-specific prostate-specific membrane antigen promoter/enhancer (PSMA E/P ) activity using green fluorescence protein reporter gene system. LNCaP, PC-3 and MCF-7 cells were transfected PSMA E/P -EGFP (enhanced green fluorescence protein) and digital images were captured of the cells in the same microscopic field under both visible and fluorescent lights as described in the Materials and methods section ( Â 200). UPRT/5-FU-targeted control of PSMAE/P treats prostate cancer FJ Zhao et al of 5-FU in all three types of cells (that is, untransfected, EGFP-expressing and UPRT-expressing LNCaP) studied and at each particular dose the inhibition was significantly higher (Po0.05) in the LNCaP cells stably expressing UPRT than the untransfected and EGFPexpressing LNCaP cells, whereas no significant difference (P40.05) was detected between the latter two cell types ( Figure 3 ). The bacterial UPRT-mediated enhancement of 5-FU efficacy was further confirmed by propidium staining and flow cytometric analysis, where 5-FU at 15 mM resulted in an elevation (Po0.05) in apoptosis in the LNCaP cells stably expressing the bacterial UPRT (46.27 ± 6.49%), as compared with the untransfected (26.63±2.49) and EGFP-expressing LNCaP (27.43 ± 1.55) cells (Table 1) .
Discussion
Discovered in 1957 18 and classified as an antimetabolite, 5-FU is one of the oldest and most frequently described chemotherapeutic drugs. However, the patients' response to 5-FU is only 10-30%, particularly when it is used alone. 19 This low response rate is largely due to the rapid degradation of the administrated drug in the cell catabolized by DPD, the rate-limiting enzyme in the catabolism of 5-FU. 8, 9 As a result, in the 5-FU-based chemotherapy it has been a significant challenge to overcome the catabolic degradation of the prodrug and improve its efficacy while without too much compromise on the drug safety by increasing the administered dose. One strategy to do so is to directly inhibit the enzymatic activity of DPD. Some early studies demonstrated indeed that coadministration of DPD inhibitors with 5-FU were able to increase the bioavailability and potentiate the therapeutic activity of 5-FU. 20, 21 However, more recent phase II/III clinical trials with several well-studied DPD inhibitors suggest that the benefits from using these inhibitors are marginal. 22 Instead of attempting to inhibit the catabolic pathway, our laboratory has been working on an alternative approach to facilitate conversion of the prodrug 5-FU into chemotherapeutically active metabolites (that is, FdUMP, FUTP and FdUTP) on the basis of the principle of suicide gene therapy, 23 thereby enhancing the drug efficacy with no need to increase its administered dose.
By definition, a suicide gene is a viral or bacterial gene whose homolog is virtually absent in mammals and whose expression in a mammalian cell is lethal to that cell. Suicide gene therapy, also known as gene-directed enzyme prodrug therapy, involves transfer into cancer cells of a suicide gene that encodes an enzyme capable of converting nontoxic prodrugs into cytotoxic drugs. Since the suicide gene therapy was first reported in 1986, 10 a number of suicide gene/prodrug systems have been developed. 23 In this study, as the first step in our effort to develop a feasible UPRT/5-FU-based suicide gene therapy for hormone-refractory prostate cancer, we evaluated the specificity and tumoricidal activity of this suicide gene/ prodrug system in an in vitro cell culture system. In the current literature, there is one paper that has already demonstrated a dramatic increase in the tumoricidal effect of 5-FU in hormone-independent prostate cancer cells expressing E. coli UPRT (either alone or in combination with cytosine deaminase) both in cell culture and nude mouse model. 15 However, in that study the transcription of the bacterial UPRT gene was controlled by the human cytomegalovirus (CMV) immediate early promoter. As this promoter is constitutively active in mammalian cells, the constitutive expression of the bacterial UPRT gene, driven by the CMV promoter, nonselectively in both tumor and normal cells greatly hampers the clinical value of the UPRT suicide gene-based chemotherapy due to considerable nonspecific cytotoxicity to normal cells.
To more specifically target prostate cancer cells, we explored the possibility of utilizing the promoter and enhancer of the human PSMA gene (PSMA E/P ) as a means of introducing the bacterial UPRT gene solely into the human PSMA-positive cells. To this end, we first examined the transcriptional activity of the PSMA E/P in two different prostate cancer cell lines (LNCaP and PC-3) and a non-prostate cancer cell line (MCF-7) using GFP as a live reporter system. By transfecting these cells with PSMA E/P -EGFP, an expression vector with the GFPcoding sequence under the control of PSMA E/P , we demonstrated that GFP was present in only LNCaP but not PC-3 and MCF-7 cells (Figure 1 ). Our observation is in agreement partially with results from a direct fluorescent microscopic study where minimal and moderate GFP expression was observed respectively in LNCaP and PC-3 cells when the GFP reporter gene was driven by the human PSMA promoter alone, whereas a UPRT/5-FU-targeted control of PSMAE/P treats prostate cancer FJ Zhao et al significantly elevated expression of GFP was seen in LNCaP but not PC-3 cells when the reporter gene was under the control of both the promoter and enhancer of the human PSMA gene. 24 Given that PSMA was highly expressed in LNCaP but not PC-3 prostate cancer cells as demonstrated by immunohistochemical analysis, 25 the profile of the reporter gene expression under the control of the human PSMA E/P in different cell lines, demonstrated in this study, confirms that the transcriptional activity of the human PSMA E/P is cell type-specific and PSMA-dependent.
We next sought to determine whether this human PSMA E/P was able to drive expression of the bacterial UPRT, leading to improvement in the drug efficacy of 5-FU in the androgen-responsive and PSMA-positive LNCaP prostate cancer cells in vitro. To do that, LNCaP cells were transfected with PSMA E/P -UPRT, a plasmid expression vector that we previously constructed in a way that the expression of the bacterial UPRT gene was placed under the control of PSMA E/P . Owing to the limited efficiency of the transient transfection, we performed neomycin-resistance selection using G418 in the transfectants and selected several stable clones whose expression of the bacterial UPRT was confirmed by RT-PCR analysis (Figure 2 ). For the purpose of control, stable clones were also similarly selected from LNCaP cells transfected with PSMA E/P -EGFP. Using these stable clones, we evaluated the functional activity of the bacterial UPRT in modulating the drug activity of 5-FU. As demonstrated by MTT assay, 5-FU inhibited cell growth in the androgen-responsive and PSMA-positive LNCaP prostate cancer cells in a dose-dependent manner, regardless of presence or absence of the bacterial UPRT, and the expression of the suicide gene UPRT significantly increased the prodrug-induced inhibition of cell growth at each of the tested doses (Figure 3) . When a fixed dose of 15 mM was chosen on the basis of the MTT assay results for further analysis of the drug cytotoxicity by flow cytometry, the exogenous UPRT significantly enhanced the capacity of 5-FU to kill the cells that expressed this enzyme (Table 1) . Compared with the study where the CMV promoter was utilized and the CMV-driven expression of the bacterial UPRT increased the sensitivity of the UPRT-expressing prostate cancer cells to 5-FU by approximately 57 times, 15 the altitude at which the drug sensitivity was enhanced by the introduced UPRT in our study was relatively smaller. This difference may be a result of a much stronger promoter activity of CMV than the endogenous human PSMA E/P in LNCaP cells.
Clinically, androgen-independent prostate cancer represents a more critical issue. Even though PSMA is not expressed in the androgen-independent prostate cancer cell line PC-3, as demonstrated in the present as well as previous studies, 25 PSMA is significantly overexpressed in androgen-independent prostate cancer and prostate cancer with higher tumor grade. 26 Therefore, we believe that the suicide gene/prodrug system, PSMA E/P -UPRT/ 5-FU, functions in all PSMA-positive prostate cancers regardless of their responsiveness to androgen.
Development of a safe, efficient, easy and inexpensive gene delivery system represents one of the most important technological challenges to gene therapists in clinical oncology. Viral vectors have been commonly used; however, due to increasing concerns over potential host immune responses to viral vectors, nonviral vectors have received more attention in recent years. Even though this study only involved in vitro analyses, our ultimate goal, as discussed above, is to develop a practical, UPRT/5-FU suicide gene/prodrug systembased therapy for metastatic prostate cancer. As a result, exploring approaches to safely and efficiently introduce the UPRT gene of E. coli origin to the metastatic prostate cancer patients will be one of our next research focuses.
In summary, for the first time in the present study we have demonstrated in an in vitro cell culture system that: (1) the promoter/enhancer of the human PSMA gene is able to drive expression of the bacterial UPRT gene specifically in androgen-responsive and PSMA-positive prostate cancer cells; and (2) the bacterial UPRT gene expressed in these cells can lead to a significant increase in the tumoricidal activity of the prodrug 5-FU. These observations have paved a solid foundation for developing a novel, UPRT/5-FU suicide gene/prodrug system-based therapeutic strategy for metastatic prostate cancer patients.
